{"doi":"10.2459/jcm.0b013e3283657524","title":"Impact of QRS duration on survival benefit with prophylactic implantable cardioverter-defibrillators","abstract":null,"journal":"Journal of Cardiovascular Medicine","year":2015,"id":635181,"datarank":0.32958368660043297,"base_score":2.1972245773362196,"endowment":2.1972245773362196,"self_citation_contribution":0.32958368660043297,"citation_network_contribution":0.0,"self_endowment_contribution":0.32958368660043297,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":8,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1647819,"name":"Sunit-Preet S. Chaudhry","orcid":null,"position":1,"is_corresponding":false},{"id":1441072,"name":"Meltiady Issa","orcid":null,"position":2,"is_corresponding":false},{"id":1647820,"name":"Megha Ambati","orcid":null,"position":3,"is_corresponding":false},{"id":1647821,"name":"Sinan Dagdelen","orcid":null,"position":4,"is_corresponding":false},{"id":233711,"name":"James C. Fang","orcid":"0000-0003-2427-9504","position":5,"is_corresponding":false},{"id":1603228,"name":"Ilke Sipahi","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Impact of QRS duration on survival benefit with prophylactic implantable cardioverter-defibrillators","abstract":"BACKGROUND: QRS duration is an important risk factor for both sudden cardiac death and all-cause mortality in patients with moderate to severe left ventricular systolic dysfunction. However, it is unknown whether baseline QRS duration can help predict the mortality benefit from implantable cardioverter-defibrillators (ICDs) when used for primary prevention purposes. OBJECTIVE: Our objective was to examine the relationship between baseline QRS duration and mortality reduction with ICDs implanted for primary prevention by performing a meta-analysis of all available randomized clinical trials. METHODS: A systematic literature search of SCOPUS (covering MEDLINE and EMBASE) was conducted for randomized controlled clinical trials involving ICDs. Primary prevention trials of systolic dysfunction that reported all-cause mortality according to subgroups on the basis of baseline QRS duration were included. RESULTS: A total of four randomized controlled clinical trials enrolling 3561 patients were included. Patients with QRS durations less than 120 ms [n = 2002, hazard ratio 0.78, 95% confidence interval (CI) 0.63-0.96, P = 0.018] and at least 120 ms (n = 1559, hazard ratio 0.59, 95% CI 0.48-0.73, P = 0.0000009) had significant decreases in all-cause mortality. On heterogeneity analysis, a strong trend for greater magnitude of benefit in patients with QRS at least 120 ms was observed (22% risk reduction vs. 41% risk reduction, P = 0.066). CONCLUSION: For primary prevention purposes, ICDs are effective in reducing all-cause mortality in moderate to severe systolic dysfunction regardless of QRS duration. However, patients with a baseline QRS duration of at least 120 ms seem to derive a greater mortality benefit from ICDs.","is_dataset_classified":null,"base_score":2.1972245773362196,"endowment":2.1972245773362196,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"25010502","pmcid":null,"openalex_id":"https://openalex.org/W2316511046","authors":[],"funders":[],"total_grants":0,"fwci":0.5623,"citation_percentile":0.71930239,"influential_citations":0,"citation_trend":[{"year":2014,"count":1},{"year":2015,"count":2},{"year":2023,"count":2},{"year":2025,"count":1},{"year":2026,"count":2}],"oa_status":"closed","license":null,"oa_locations":[{"url":"https://journals.lww.com/10.2459/JCM.0b013e3283657524","host_type":"publisher"},{"url":"https://doi.org/10.2459/jcm.0b013e3283657524","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/25010502","host_type":"repository"}],"fields_of_study":["Cardiac pacing and defibrillation studies","Cardiac electrophysiology and arrhythmias","Cardiac Arrhythmias and Treatments","Death, Sudden, Cardiac","Defibrillators, Implantable","Electrocardiography","Heart Failure","Humans","Primary Prevention","Prognosis","Randomized Controlled Trials as Topic"],"mesh_terms":["Electrocardiography","Heart Failure","Humans","Primary Prevention","Prognosis","Randomized Controlled Trials as Topic","Death, Sudden, Cardiac","Defibrillators, Implantable"],"keywords":["Medicine","QRS complex","Hazard ratio","Internal medicine","Cardiology","Randomized controlled trial","Confidence interval","Meta-analysis","Implantable cardioverter-defibrillator","Clinical trial"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-06T14:45:08.529127Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}